DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.52 Million USD | 301.6% |
| 2022 | 1.12 Million USD | -84.23% |
| 2021 | 7.14 Million USD | -35.26% |
| 2020 | 11.03 Million EUR | -51.45% |
| 2019 | 22.73 Million EUR | 1455.47% |
| 2018 | 1.46 Million EUR | -33.23% |
| 2017 | 2.18 Million EUR | -48.58% |
| 2016 | 4.25 Million EUR | -17.01% |
| 2015 | 5.13 Million EUR | 8.52% |
| 2014 | 4.72 Million EUR | 160.07% |
| 2013 | 1.81 Million EUR | 264.96% |
| 2012 | 498.12 Thousand EUR | -38.14% |
| 2011 | 805.23 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 6.78 Million EUR | 0.0% |
| 2024 Q1 | 6.79 Million USD | 0.0% |
| 2023 Q2 | 187 Thousand USD | -72.5% |
| 2023 Q1 | 680 Thousand USD | -39.66% |
| 2023 FY | 4.52 Million USD | 301.6% |
| 2023 Q4 | 4.52 Million USD | 4714.89% |
| 2023 Q3 | 94 Thousand USD | -49.73% |
| 2022 FY | 1.12 Million USD | -84.23% |
| 2022 Q4 | 1.12 Million USD | -20.8% |
| 2022 Q1 | 2.26 Million USD | -68.27% |
| 2022 Q2 | 1.94 Million USD | -14.24% |
| 2022 Q3 | 1.42 Million USD | -26.84% |
| 2021 Q2 | 9.33 Million USD | -5.58% |
| 2021 Q1 | 9.88 Million USD | -10.47% |
| 2021 Q3 | 8.29 Million USD | -11.08% |
| 2021 Q4 | 7.14 Million USD | -13.87% |
| 2021 FY | 7.14 Million USD | -35.26% |
| 2020 Q4 | 11.03 Million EUR | 0.0% |
| 2020 Q2 | 20.93 Million EUR | 0.0% |
| 2020 FY | 11.03 Million EUR | -51.45% |
| 2019 Q4 | 22.73 Million EUR | -2.76% |
| 2019 Q2 | 25.06 Million EUR | 0.0% |
| 2019 Q3 | 23.38 Million EUR | -6.69% |
| 2019 FY | 22.73 Million EUR | 1455.47% |
| 2018 FY | 1.46 Million EUR | -33.23% |
| 2018 Q4 | 1.46 Million EUR | 0.0% |
| 2018 Q2 | 1.79 Million EUR | 0.0% |
| 2017 Q2 | 4.27 Million EUR | 0.0% |
| 2017 Q4 | 2.18 Million EUR | 0.0% |
| 2017 FY | 2.18 Million EUR | -48.58% |
| 2016 Q4 | 4.25 Million EUR | 0.0% |
| 2016 FY | 4.25 Million EUR | -17.01% |
| 2016 Q2 | 4.86 Million EUR | 0.0% |
| 2015 Q4 | 5.13 Million EUR | 0.0% |
| 2015 Q2 | 5.29 Million EUR | 0.0% |
| 2015 FY | 5.13 Million EUR | 8.52% |
| 2014 Q2 | 1.78 Million EUR | 0.0% |
| 2014 Q4 | 4.72 Million EUR | 0.0% |
| 2014 FY | 4.72 Million EUR | 160.07% |
| 2013 FY | 1.81 Million EUR | 264.96% |
| 2013 Q4 | 1.81 Million EUR | 0.0% |
| 2013 Q2 | 1.83 Million EUR | 0.0% |
| 2012 Q4 | 498.12 Thousand EUR | 0.0% |
| 2012 FY | 498.12 Thousand EUR | -38.14% |
| 2012 Q2 | 472.26 Thousand EUR | 0.0% |
| 2011 Q4 | 805.23 Thousand EUR | 0.0% |
| 2011 FY | 805.23 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -311.081% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 89.874% |
| Adocia SA | 4.54 Million EUR | 0.308% |
| Aelis Farma SA | 2.04 Million EUR | -120.996% |
| Biophytis S.A. | 3.11 Million EUR | -45.484% |
| Advicenne S.A. | 15.89 Million EUR | 71.527% |
| genOway Société anonyme | 5.51 Million EUR | 17.997% |
| IntegraGen SA | 642.28 Thousand EUR | -604.677% |
| Medesis Pharma S.A. | 1.2 Million EUR | -277.167% |
| Neovacs S.A. | 650 Thousand EUR | -596.308% |
| NFL Biosciences SA | 39.2 Thousand EUR | -11445.035% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -3.891% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -130.88% |
| Sensorion SA | 1.24 Million EUR | -264.732% |
| Theranexus Société Anonyme | 2.46 Million EUR | -83.93% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -16.111% |
| TheraVet SA | 1 Million EUR | -352.329% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 34.463% |
| argenx SE | 15.35 Million EUR | 70.522% |
| BioSenic S.A. | 15.57 Million EUR | 70.937% |
| Celyad Oncology SA | 902 Thousand EUR | -401.774% |
| Galapagos NV | 4.94 Million EUR | 8.455% |
| Genfit S.A. | 62.25 Million EUR | 92.73% |
| GeNeuro SA | 6.49 Million EUR | 30.287% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1215.698% |
| Innate Pharma S.A. | 30.6 Million EUR | 85.213% |
| Inventiva S.A. | 25.61 Million EUR | 82.331% |
| MaaT Pharma SA | 5.42 Million EUR | 16.571% |
| MedinCell S.A. | 52.8 Million EUR | 91.428% |
| Nanobiotix S.A. | 41.66 Million EUR | 89.136% |
| Onward Medical N.V. | 16.3 Million EUR | 72.243% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -31.165% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 87.254% |
| Oxurion NV | 117 Thousand EUR | -3768.376% |
| Pharming Group N.V. | 123.65 Million EUR | 96.34% |
| Poxel S.A. | 40.14 Million EUR | 88.725% |
| GenSight Biologics S.A. | 1.04 Million EUR | -331.87% |
| Transgene SA | 17 Thousand EUR | -26523.529% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.843% |
| Valneva SE | 132.76 Million EUR | 96.591% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |